User profiles for Yves Durocher
 | Yves DurocherNRC - Human Health Therapeutics Research Center Verified email at nrc.gc.ca Cited by 11907 |
Large-scale transfection of mammalian cells for the fast production of recombinant protein
PL Pham, A Kamen, Y Durocher - Molecular biotechnology, 2006 - Springer
Recombinant proteins (r-proteins) are increasingly important in fundamental research and
for clinical applications. As many of these r-proteins are of human or animal origin, cultivated …
for clinical applications. As many of these r-proteins are of human or animal origin, cultivated …
Expression systems for therapeutic glycoprotein production
Y Durocher, M Butler - Current opinion in biotechnology, 2009 - Elsevier
There are slightly over 165 recombinant pharmaceuticals currently approved for human use.
Another 500 protein candidates are in preclinical and clinical development, about 70% of …
Another 500 protein candidates are in preclinical and clinical development, about 70% of …
Transient expression and purification of chimeric heavy chain antibodies
…, TN Baral, A Azizi, J Li, B Cass, Y Durocher - Protein Expression and …, 2009 - Elsevier
Monoclonal antibodies have been successfully engineered as approved therapeutics.
However, their large size is considered a major factor preventing them from having a more …
However, their large size is considered a major factor preventing them from having a more …
Development of a scalable process for high‐yield lentiviral vector production by transient transfection of HEK293 suspension cultures
…, J Transfiguracion, Y Durocher… - The Journal of Gene …, 2009 - Wiley Online Library
Background Lentiviral vectors (LV) offer several advantages over other gene delivery vectors.
Their potential for the integration and long‐term expression of therapeutic genes renders …
Their potential for the integration and long‐term expression of therapeutic genes renders …
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients
While the antibody response to SARS-CoV-2 has been extensively studied in blood,
relatively little is known about the antibody response in saliva and its relationship to systemic …
relatively little is known about the antibody response in saliva and its relationship to systemic …
[HTML][HTML] A simple protein-based surrogate neutralization assay for SARS-CoV-2
Most of the patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
mount a humoral immune response to the virus within a few weeks of infection, but the …
mount a humoral immune response to the virus within a few weeks of infection, but the …
High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells
Y Durocher, S Perret, A Kamen - Nucleic acids research, 2002 - academic.oup.com
A scalable transfection procedure using polyethylenimine (PEI) is described for the human
embryonic kidney 293 cell line grown in suspension. Green fluorescent protein (GFP) and …
embryonic kidney 293 cell line grown in suspension. Green fluorescent protein (GFP) and …
A scalable serology solution for profiling humoral immune responses to SARS‐CoV‐2 infection and vaccination
Objectives Antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
has been instrumental in detecting previous exposures and analyzing vaccine‐…
has been instrumental in detecting previous exposures and analyzing vaccine‐…
MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons
…, V Shridhar, DI Smith, J Kelly, Y Durocher… - Journal of Molecular …, 2003 - Springer
We describe the discovery of a novel, 20 kDa, secreted human protein named mesencephalic
astrocyte-derived neurotrophic factor, or MANF. The homologous, native molecule was …
astrocyte-derived neurotrophic factor, or MANF. The homologous, native molecule was …
Relative ratios of human seasonal coronavirus antibodies predict the efficiency of cross-neutralization of SARS-CoV-2 spike binding to ACE2
…, M Greig, M McGuinty, RA Booth, Y Durocher… - …, 2021 - thelancet.com
Background Antibodies raised against human seasonal coronaviruses (sCoVs), which are
responsible for the common cold, are known to cross-react with SARS-CoV-2 antigens. This …
responsible for the common cold, are known to cross-react with SARS-CoV-2 antigens. This …
